CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY [Yahoo! Finance]
Cumberland Pharmaceuticals Inc. (CPIX)
Last cumberland pharmaceuticals inc. earnings: 3/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.shareholder.com/cpix/index.cfm
Company Research
Source: Yahoo! Finance
that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Cumberland is completing the FIGHT DMD™ trial , a multicenter, double-blind, placebo-controlled Phase II study investigating the pharmacokinetics, safety and efficacy of once daily oral Ifetroban in patients with DMD. Results will be announced later this year. "For Duchenne muscular dystrophy, a devastating genetic disorder affecting young boys, securing both Orphan Drug and Rare Pediatric Disease Designations for Ifetroban from the FDA is a critical step forward," said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. "These designations not only recognize the urgent need for effective treatments but also provide vital support to accelerate research and development. These important regulatory milestones represent hope for families a
Show less
Read more
Impact Snapshot
Event Time:
CPIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPIX alerts
High impacting Cumberland Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
CPIX
News
- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Pharma Stock Soars On Phase 2 Announcement [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart DiseasePR Newswire
- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
CPIX
Sec Filings
- 2/14/25 - Form 424B5
- 2/14/25 - Form 8-K
- 2/13/25 - Form SCHEDULE
- CPIX's page on the SEC website